已发表论文

治疗前的血小板计数可作为胰腺癌患者的预后因素:系统评价和荟萃分析

 

Authors Chen S, Na N, Jian Z

Received 29 July 2017

Accepted for publication 27 October 2017

Published 21 December 2017 Volume 2018:11 Pages 59—65

DOI https://doi.org/10.2147/OTT.S147715

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Amy Norman

Peer reviewer comments 2

Editor who approved publication: Dr Ingrid Espinoza

Background: The relationship between platelet counts and pancreatic cancer as a prognostic factor has been reported in many studies. We aimed to evaluate the prognostic value of platelet counts in predicting the prognosis of pancreatic cancer patients.
Methods: We searched PubMed, Medline, EMBASE, and Google Scholar for eligible studies up to May 2017. Information about the characteristics of the study and relevant outcomes was extracted. A meta-analysis was performed to analyze the prognostic value of platelet counts using the hazard ratio (HR) and 95% confidence intervals (CIs).
Results: A total of 1,756 patients in 13 retrospective studies were included. The pooled HR of 1.51 (95% CI: 1.20–1.90, <0.001) showed that patients with elevated platelet counts were expected to have poor overall survival after treatment. Subgroup analysis showed that prognostic value of platelet levels was stronger in patients who received surgical resection (HR =1.60, 95% CI: 1.09–2.34, =0.02), followed by patients who received palliative therapy (HR =1.46, 95% CI: 1.03–2.06, =0.03).
Conclusion: Platelet counts could be a useful prognostic marker for pancreatic cancer. Patients with high platelet counts are expected to have poor survival.
Keywords: pancreatic adenocarcinoma, blood parameters, platelet, prognosis, evidence-based medicine